Wedbush Morgan Reiterates a 'Buy' on Biodel (BIOD)
More News related to BIOD
- Wedbush Reiterates an 'Outperform' on Biodel (BIOD); Comments on VIAjectT
- Unusual 11 Mid-Day Movers 3/25: CBG, MIC, JBL, HW Higher; DRYS, AIG, AMN, FTBK Lower
- Morning Movers 3/25: CBG, BIOD, ACAS, BBI, AMD Higher; DRYS, SOLF, STZ, CYPB, DSW Lower
- Biodel (BIOD) Plans to Submit NDA for VIAject(R) to FDA
- Wedbush Morgan Reiterates a 'Buy' on Biodel (BIOD)
More News related to Analyst Comments
- Sign of the Times: U.S. Mint Has To Temporarily Suspend Sales of One Ounce Gold Coins Due to Demand
- The EUR/USD is now at $1.51 a 52-week high
- Central Banks Continue Snapping Up Gold, Sri Lanka Buys 10 Metric Tons From IMF
- Bloomingdale's Chairman Sees Jewelry Sales Up 20% at the End of November, Calls Consumer 'Confident'
- Research Firm Questions Surge In Origin Agritech (SEED)
Wedbush Morgan reiterates a 'Buy' on Biodel (Nasdaq: BIOD). Price target $10.
Wedbush analyst says, "Management guided to announcing VIAject regulatory announcement in March. We believe a transforming VIAject partnership announcement could follow in 2009. We anticipate other catalysts in 2009."
Biodel Inc. (Biodel) is a development-stage specialty pharmaceutical company located in Danbury, Connecticut.
Related Categories
Analyst CommentsStocks Mentioned
+0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
